NM-2201

NM-2201_structure.png

NM-2201 is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. NM-2201 is chemically related to other synthetic cannabinoids such as 5F-AMB and AB-FUBINACA.

Chemical Structure

NM-2201 is classified as an indole-based synthetic cannabinoid. Its chemical structure includes a naphthoyl group, which is a common feature in many synthetic cannabinoids. The full chemical name of NM-2201 is Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate.

Pharmacology

NM-2201 acts as a full agonist at the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system. This system is involved in regulating various physiological processes including pain, mood, and appetite. The activation of these receptors by NM-2201 can lead to effects similar to those produced by tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Legal Status

The legal status of NM-2201 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. For example, in the United States, NM-2201 is listed as a Schedule I substance under the Controlled Substances Act.

Health Risks

The use of NM-2201 has been associated with various adverse health effects. These can include tachycardia, hypertension, nausea, vomiting, and psychosis. Due to its potency and the variability in the composition of products containing NM-2201, there is a significant risk of overdose and severe toxicity.

Detection in Biological Fluids

NM-2201 and its metabolites can be detected in biological fluids such as urine and blood using techniques like gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods are commonly used in forensic toxicology to confirm the presence of synthetic cannabinoids.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• Controlled Substances Act